leadf
logo-loader
viewArix Bioscience PLC

Arix Bioscience says portfolio company Atox Bio plans NDA submission for Reltecimod drug in third quarter of 2020

The plans follow results from a phase 3 clinical trial of Reltecimod which showed positive effects on resolution of organ dysfunction in patients suffering with necrotizing soft tissue infection

Arix Bioscience PLC - Arix Bioscience portfolio company Atox Bio plans NDA submission for Reltecimod drug in third quarter of 2020

Arix Bioscience PLC (LON:ARIX) has said its portfolio company, Atox Bio, is planning to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) for its Reltecimod drug in the third quarter of 2020 under an accelerated approval pathway.

The plans follow results from a phase 3 clinical trial of Reltecimod which showed positive effects on resolution of organ dysfunction in patients suffering with necrotizing soft tissue infection.

READ: Arix Biosciences portfolio company VelosBio completes US$137mln Series B financing

The Phase 3 results showed that Atox’s Reltecimod, in conjunction with currently available standard of care demonstrated, a “significant difference” in the percentage of patients who achieved resolution of organ dysfunction/failure by day 14 versus standard of care alone.

Atox added that Reltecimod was "well-tolerated" in patients, who also demonstrated an improvement in hospital discharge status versus a placebo.

Arix Bioscience shares were 0.6% higher at 87p in early trading on Friday.

Quick facts: Arix Bioscience PLC

Price: 151 GBX

LSE:ARIX
Market: LSE
Market Cap: £204.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE flounders as imminent Brexit talks loom

The FTSE is mixed this Tuesday despite the weaker pound. Sterling is still battling no deal Brexit fears as the UK Prime Minister Boris Johnson threatens that if no progress on the talks with the EU is made week, preparations for a no deal will be ramped up. Britain’s biggest sports retailer...

on 8/9/20

2 min read